NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

BACKGROUND: The prognosis for patients with poorly-differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy with no standard second-line (2L) treatment. METHODS: Patients with his...

Descripción completa

Detalles Bibliográficos
Autores principales: McNamara, Mairéad G., Swain, Jayne, Craig, Zoe, Sharma, Rohini, Faluyi, Olusola, Wadsley, Jonathan, Morgan, Carys, Wall, Lucy R., Chau, Ian, Reed, Nick, Sarker, Debashis, Margetts, Jane, Krell, Daniel, Cave, Judith, Sothi, Sharmila, Anthoney, Alan, Bell, Christopher, Patel, Alkesh, Oughton, Jamie B., Cairns, David A., Mansoor, Wasat, Lamarca, Angela, Hubner, Richard A., Valle, Juan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242623/
https://www.ncbi.nlm.nih.gov/pubmed/37287870
http://dx.doi.org/10.1016/j.eclinm.2023.102015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242623/
https://www.ncbi.nlm.nih.gov/pubmed/37287870
http://dx.doi.org/10.1016/j.eclinm.2023.102015

Ejemplares similares